Expanding Role of Delta-Like 4 Mediated Notch Signaling in Cardiovascular and Metabolic Diseases

Daiju Fukuda, MD, PhD; Masanori Aikawa, MD, PhD

Cardiometabolic disease, a global health threat, has been linked to chronic inflammation, in which activated macrophages play a key role. Macrophages are highly heterogeneous hematopoietic cells found in nearly every tissue in the body. Various stimuli recruit monocytes into the cardiovascular system and metabolic organs, where they differentiate to macrophages, and activate these pro-inflammatory phagocytes, leading to the initiation and development of inflammation in these organs. Key regulators of macrophage activation therefore may serve as therapeutic targets for cardiometabolic disease. The Notch signaling pathway, involving 5 ligands and 4 receptors, regulates the differentiation of various cell types during development, and also contributes to the disease processes in adults. We found that the Notch ligand delta-like 4 (Dll4) activates macrophages in vitro as determined by the induction of genes and pathways associated with cardiovascular and metabolic disorders. Our recent study demonstrated in vivo that blockade of Dll4 by a neutralizing antibody attenuates key features typical of cardiovascular and metabolic diseases, such as accumulation of activated macrophages in arteries and fat; chronic atherosclerosis; arterial and valvular calcification; insulin resistance; and fatty liver. These results suggest that Dll4-mediated Notch signaling participates in the shared disease mechanisms for cardiovascular and metabolic disorders. This review summarizes the role of macrophages and Dll4/Notch signaling in the development of inflammation in both the cardiovascular system and metabolic organs. (Circ J 2013; 77: 2462–2468)

Key Words: Atherosclerosis; Inflammation; Metabolic syndrome

C

hronic inflammation, in which macrophages play a key role, is associated with a disease complex known as “cardiometabolic syndrome” and is characterized by atherosclerosis, obesity, insulin resistance, and fatty liver. Macrophages accumulate in the vascular system and metabolic organs, and are activated through various cellular and molecular pathways. Despite much effort to elucidate these mechanisms, knowledge remains limited, and no satisfactory therapeutic strategies are available. Notch signaling involves a highly preserved pathway among species and influences cell fate decisions, cell proliferation, differentiation, and apoptosis. Notch receptors (Notch1, Notch2, Notch3, and Notch4) and ligands (Jagged1, Jagged2, Delta-like 1 [Dll1], Dll3, Dll4) have diverse functions in physiological and biological conditions. We demonstrated that in cultured human primary macrophages, the Notch ligand Dll4 triggers various pro-inflammatory effects associated with atherosclerosis and metabolic disorders. We further demonstrated that blockade of Dll4-mediated Notch signaling inhibited the development of atherosclerosis and insulin resistance in vivo. Dll4 was initially considered as an endothelial cell-specific Notch ligand that contributes to angiogenesis. The roles of Dll4-mediated Notch signaling in vascular development and cancer angiogenesis have been reviewed extensively. In this review, we aim to summarize the role of macrophages in the development of inflammation in both the cardiovascular system and metabolic organs, and to present our recent progress in demonstrating the role of Dll4-mediated Notch signaling in macrophage activation.

Role of Macrophages in the Development of Cardiovascular and Metabolic Disorders

Accumulating evidence supports the premise that chronic inflammation is central to the pathobiology of atherosclerotic vascular disease and metabolic disorders. In the context of atherosclerosis, activated macrophages participate critically in every stage of lesion progression, from early fatty streak formation to the acute onset of plaque rupture and thrombosis. Extensive studies have demonstrated that monocyte chemoattractant protein-1 (MCP-1), a potent chemokine secreted from activated endothelial cells, promotes the recruitment of circulating monocytes into the arterial vessel wall as one of the initial major events leading to atherosclerotic vascular diseases. Matrix-degrading enzymes and prothrombotic molecules elaborated from activated macrophages promote plaque disruption and...
subsequent thrombosis. Moreover, macrophage proliferation may contribute to the development of inflamed plaque. Additionally, macrophages secrete various pro-inflammatory cytokines, such as interleukin 1β (IL-1β), that induce atherothrombosis-associated molecules through the activation of endothelial cells, smooth muscle cells, and macrophages themselves. Macrophage-derived MCP-1 may recruit more monocytes into inflamed plaques. Thus, macrophages participate in an amplification cascade that sustains the inflammatory response in the atherosclerotic plaque and promotes its structural instability and thrombogenicity.

The macrophage is also the primary cell type responsible for inflammatory responses in adipose tissue. Many cellular and molecular responses, accompanied by increased adiposity (e.g., elevation of saturated fatty acid levels, endoplasmic reticulum stress, and decreased local oxygen pressure) increase chemokine expression in adipose tissue. MCP-1 and its receptor, CC chemokine receptor 2 (CCR2), are the most critical chemokines in the development of insulin resistance. Many previous studies using loss-of-function and gain-of-function models have revealed that MCP-1 triggers macrophage accumulation, which reached 40–50% of the total stromal vascular fraction (SVF). Once accumulated in adipose tissue, macrophages respond to many inflammatory milieus and secrete pro-inflammatory molecules, such as MCP-1, tumor necrosis factor-α (TNF-α), and IL-6. These inflammatory molecules further promote inflammation in adipose tissue. Recent studies also demonstrated a paracrine loop involving saturated fatty acids and TNF-α derived from adipocytes and macrophages, respectively, that establishes a vicious cycle that augments the inflammatory changes in adipose tissue, leading to the development of insulin resistance.

Thus, chronic inflammation, especially macrophage accumulation and activation, participates in the development of both atherosclerotic diseases and metabolic disorders. Several studies have suggested that inflammatory changes in adipose tissue can influence systemic inflammatory states such as atherosclerosis, but the precise mechanisms by which adipose tissue inflammation causes systemic inflammation remain unknown, and the shared mechanisms that initiate or accelerate the inflammatory milieu in both the vasculature and metabolic organs have not been fully investigated. Exploring possible links between atherosclerosis and metabolic disorders may help to establish new therapeutic strategies for this global health threat.

**Macrophage Heterogeneity**

Macrophages are a highly heterogeneous cell population. Originating from bone marrow cells, they reside in nearly every tissue and organ in the human body. Tissue-resident macrophages, such as Kupffer cells in the liver and microglia in the neuronal system, adapt to their local environment and have distinct characteristics, including functional and morphological phenotypes. These resident macrophages sense signs of infection or tissue damage. The characteristics and functions of macrophages that infiltrate the cardiovascular system and metabolic organs in response to the inflammatory milieu and cause cardiovascular and metabolic disorders are different from those of resident macrophages. In the presence of cardiovascular and/or metabolic dysfunction, cells in metabolic organs (i.e., adipocytes and endothelial cells) express chemokines, including MCP-1, which recruit circulating monocytes to the organ and stimulate differentiation to macrophages. These recruited macrophages are activated by different stimuli and exhibit various activation states.

Recent advances in immunology have suggested a more complicated classification of macrophage activation, but 2 well-established and commonly-used polarization patterns include classically activated (M1) macrophages and alternately activated (M2) macrophages. Bacterial lipopolysaccharide (LPS) or Th1 cytokines (e.g., interferon γ [IFN-γ]) induce M1 polarization. M1 macrophages produce pro-inflammatory mediators such as TNF-α, IL-1β, IL-6, matrix metalloproteinase 9 (MMP-9), and inducible nitric oxide synthase (iNOS). In contrast, Th2 cytokines (e.g., IL-4) induce M2 polarization, leading to the production of anti-inflammatory mediators, notably IL-10.

Emerging evidence suggests close links between the M1/M2 paradigm and vascular and metabolic diseases. In 2007, several groups used hyperlipidemic mice to demonstrate that hyperlipidemia polarizes monocytes/macrophages to an M1-activated phenotype and associates with the development of atherosclerosis. Other studies demonstrated that pro-inflammatory macrophage polarization may induce atherogenesis and plaque destabilization through collagen loss and calcification in plaques. Dietary fatty acids also polarize macrophages towards M1 or M2 activation states, depending on the presence of carbon-carbon double bonds (saturated/unsaturated) or their length, thus providing a molecular basis for the crosstalk between metabolic and inflammatory pathways that are associated with the development of insulin resistance. These studies demonstrated the pivotal role of macrophages and their polarization in the development and prevention of cardiometabolic disorders. Excessive polarization of macrophages toward the pro-inflammatory M1 state in an organ may contribute to the pathogenesis of cardiovascular and metabolic diseases, whereas a microenvironment with a dominance of M2 macrophage polarization may inhibit these diseases.

Recent advances in immunology have dissected the molecular and cellular mechanisms for the development of cardiometabolic inflammation, although information related to the precise mechanisms of the regulation of the M1/M2 macrophage balance remains limited. Furthermore, recent studies have suggested that the balance of M1/M2 activation is not steady. Foster et al reported that macrophages lose the ability to produce pro-inflammatory cytokines following re-stimulation after repeated LPS treatment, even though they can produce other genes, including IL-10. This phenomenon may be associated with the mechanism for endotoxin tolerance. Furthermore, whether M1 or M2 activated macrophages can switch their phenotypes remains obscure, particularly in vivo. Because the polarization shift to M1 macrophages closely relates to the pathophysiology of inflammation in cardiovascular system and metabolic organs, finding key molecular switches may provide potential therapeutic strategies. Despite accumulating evidence and its large clinical impact, in vivo mechanisms for macrophage polarization remain incompletely understood. Thus, further studies are needed to reveal the molecular basis of macrophage polarization.

**Overview of Notch Signaling**

The Notch pathway, one of the most fundamental cell signal transduction mechanisms, regulates embryonic development and differentiation of various cell types and organs. Activation of Notch signaling requires cell-to-cell contact (Figure 1). In mammals, the pathway involves 5 ligands (Jagged1, Jagged2, Dll1, Dll3, and Dll4) and 4 receptors (Notch1, Notch2, Notch3, and Notch4). Notch signaling occurs when a ligand (e.g., Dll4) of a sending cell binds to the extracellular domain of a receptor (e.g., Notch3) expressed on a receiving cell. This binding
Notch Signaling in Cardiovascular Diseases

Notch signaling may participate in the pathogenesis of cardiovascular diseases. Several studies have demonstrated that Notch signaling contributes to smooth muscle cell differentiation and proliferation, leading to vascular calcification and neointimal hyperplasia after injury. It is also involved in the development of atherosclerosis. Dll4 is normally induced by vascular endothelial growth factor (VEGF), and is a negative-feedback regulator that restrains vascular sprouting and branching. Consistent with this role, deletion or inhibition of Dll4 results in excessive, nonproductive angiogenesis. This unrestrained angiogenesis unexpectedly and paradoxically decreases tumor growth, even in tumors resistant to anti-VEGF therapies. Furthermore, among the previous studies on the diverse roles of Notch signaling in physiology and pathology, recent reports have suggested that Notch signaling has metabolic functions, and that Notch inhibition is beneficial in the treatment of insulin resistance. Taken together, Notch signaling components appear to have expanded roles in disease mechanisms, offering possible therapeutic targets for various disorders.

Table. Involvement of Notch Signaling in Adult Diseases

<table>
<thead>
<tr>
<th>Cell/organ type</th>
<th>Related disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrophages</td>
<td>Atherosclerosis, metabolic diseases</td>
</tr>
<tr>
<td>T lymphocytes</td>
<td>Acute T-lymphoblastic leukemia, autoimmune disease</td>
</tr>
<tr>
<td>B lymphocytes</td>
<td>Chronic B-lymphoblastic leukemia</td>
</tr>
<tr>
<td>Smooth muscle cells</td>
<td>Remodeling after vascular injury, Alagille syndrome</td>
</tr>
<tr>
<td>Endothelial cells</td>
<td>Angiogenesis</td>
</tr>
<tr>
<td>Neural system</td>
<td>Alzheimer’s disease, Cadasil, multiple sclerosis</td>
</tr>
<tr>
<td>Cardiovascular system</td>
<td>Valvular disease, cardiomyopathy</td>
</tr>
<tr>
<td>Muscle</td>
<td>Muscular dystrophy</td>
</tr>
<tr>
<td>Skin</td>
<td>Cancer (basal cell carcinoma, squamous cell carcinoma)</td>
</tr>
</tbody>
</table>

Many studies have revealed links between mutations of Notch receptors/ligands and various diseases (Table). Many studies also have shown that Notch signaling contributes to tumorigenesis, angiogenesis, and tissue regeneration after injury. A recent series showed that Dll4 is normally induced by vascular endothelial growth factor (VEGF), and is a negative-feedback regulator that restrains vascular sprouting and branching. Consistent with this role, deletion or inhibition of Dll4 results in excessive, nonproductive angiogenesis. This unrestrained angiogenesis unexpectedly and paradoxically decreases tumor growth, even in tumors resistant to anti-VEGF therapies. Furthermore, among the previous studies on the diverse roles of Notch signaling in physiology and pathology, recent reports have suggested that Notch signaling has metabolic functions, and that Notch inhibition is beneficial in the treatment of insulin resistance. Taken together, Notch signaling components appear to have expanded roles in disease mechanisms, offering possible therapeutic targets for various disorders.

Figure 1. Notch signaling pathway. Interaction of Notch receptors with their ligands triggers a cascade of enzymatic cleavages of the receptor by ADAM family proteinases and the γ-secretase complex, which allow the Notch intracellular domain (NICD) to migrate into the nucleus. In the nucleus, NICD associates with a transcription factor, RBP-Jκ (also known as CSL for CBF1/Su(H)/Lag-1), and activates transcription from the RBP-Jκ DNA binding site.
signaling is necessary for the maintenance and differentiation of hematopoietic stem cells. In particular, T-lymphocyte commitment and maturation has been extensively studied. It has been reported that Dll4 or Dll4 expressed on antigen-presenting cells (APCs) promote Th1 cell differentiation. Th1 cells and Th1 cytokines produced by these cells accelerate cardiovascular inflammation. On the other hand, Jagged ligands on APCs promote Th2 cell differentiation, which may suppress inflammatory responses in the cardiovascular system. Various cell types and biological processes contribute to the pathogenesis of cardiovascular disease; therefore, investigating the role of Notch signaling may provide new insight into the mechanisms of these diseases.

Dll4-Mediated Notch Signaling and Macrophage Activation
The Notch pathway mediates juxtacrine signaling that requires cell-to-cell contact. Previous immunohistochemical and ultrastructural studies have clearly demonstrated direct membrane contact between adjacent macrophages, which supports a role for homotypic juxtacrine communication between macrophages in inflamed tissues. We therefore tested the hypothesis that activation of macrophages, a critical process for the initiation and development of atherosclerosis, involves Notch signaling. In our previous study, quantitative immunohistochemical analyses in human carotid atherosclerotic lesions localized Dll4 and other Notch components in macrophages. We found that macrophages in human atherosclerotic plaques express various Notch pathway components. Although Dll4 had been considered as an endothelial cell-specific Notch ligand, we demonstrated in vitro that human primary macrophages express Dll4 upon activation. Dll4 expression increased in macrophages exposed to pro-inflammatory stimuli such as LPS, IL-1β, or minimally modified low-density lipoprotein (LDLr), in a toll-like receptor 4- and nuclear factor (NF)-κB-dependent fashion. What is the functionality of Dll4 in macrophages? Co-incubation of macrophages with cells expressing Dll4 triggered Notch proteolysis and activation, leading to the induction of pro-inflammatory molecules and pathways such as the typical M1 gene iNOS, mitogen-activated protein kinase, Akt, and NF-κB. Interestingly, Dll4 ligation to macrophages promoted the expression of Dll4 itself. These findings led to our working hypothesis that Dll4-triggered Notch signaling mediates inflammatory responses by accelerating a positive feedback loop of macrophage activation, leading to the development of atherosclerotic vascular diseases, metabolic disorders, and other inflammatory diseases. More recent studies have also demonstrated the contribution of the Notch signaling to the pathogenesis of inflammation.

Dll4-Mediated Notch Signaling and Cardiovascular and Metabolic Disorders
The Notch pathway regulates embryonic development and differentiation of various cell types and organs. Such critical cell signaling pathways often play a role in normal adult homeostasis and disease processes in major organs. As mentioned before, we found that in cultured macrophages the Notch ligand Dll4 triggers various pro-inflammatory effects associated with atherosclerosis and metabolic disorders. We therefore hypothesized that Dll4-mediated Notch signaling participates in shared mechanisms for inflammation in the cardiovascular system and metabolic organs, thus serving as a novel therapeutic target. Investigation of the in vivo role of Dll4-mediated Notch signaling in the pathogenesis of cardiovascular and metabolic disorders used administration of the neutralizing anti-Dll4 antibody to LDLr receptor-deficient (Ldlr<sup>-/-</sup>) mice fed a high-fat, high-cholesterol diet, an established model for atherosclerosis and metabolic disturbances in humans. Unlike pan-Notch inhibitors (eg, γ-secretase inhibitors), which cause severe and potentially fatal gut toxicity and thymus atrophy, our Dll4 antibody did not exert any obvious adverse effects and was well tolerated. This approach enabled us to circumvent the embryonic lethality of Dll4 deficiency and provided clinically translatable evidence for the pro-inflammatory role of Dll4.

Dll4 blockade reduced the size of atherosclerotic lesions in the aorta. Furthermore, Dll4 antibody treatment markedly decreased MCP-1 expression and macrophage accumulation in atherosclerotic lesions. Macrophages play a pivotal role in the destabilization of atherosclerotic plaques, leading to the disruption of atherosclerotic plaques and acute thrombotic complications. We and others have established the role of macrophage-derived proteinases, including matrix metalloproteinase 13 (MMP-13), in such plaque “vulnerability” by the induction of loss of fibrilar collagen, a critical determinant of arterial integrity. The early stage of calcification in arteries (‘microcalcification’) may decrease plaque stability and cause plaque disruption. Several studies, including our own, have shown that macrophages promote arterial calcification. Other evidence of indirect suggest that Notch signaling also regulates calcification. Dll4 antibody treatment decreased the collagen loss and calcification of plaques, suggesting a role of Notch signaling in 2 major processes for plaque instability and disruption. Consistent with reduction of collagen loss and calcification, Dll4 antibody treatment reduced the expression of MMP-9 and MMP-13, the enzymes responsible for collagen degradation in plaques, and reduced osteogenic regulators such as Cbfa-1 and osteocalcin and bone morphogenetic proteins (BMPs) in the aorta. Dll4 antibody also decreased the expression of BMP-2 and MMP-9 in peritoneal macrophages. Furthermore, in macrophages, siRNA against Dll4 reduced MMP-9 expression, whereas overexpression of Dll4 or exogenous immobilized recombinant Dll4 (rDll4) tended to increase this matrix-degrading enzyme. These results suggest that Dll4-mediated Notch signaling serves as an important instigator for the instability and clinical complications of atherosclerotic plaques.

The same treatment also decreased MCP-1 expression and macrophage accumulation in adipose tissue, which was associated with reduced excessive fat deposition and decreased insulin resistance. Dll4 blockade did not affect food intake. Accompanying the improvement in insulin sensitivity, the expression of adiponectin, GLUT4, C/EBPα, and IRS-1, each of which correlates with insulin sensitivity, increased in the adipose tissue of antibody-treated mice. To our surprise, Dll4 blockade also improved the major features of fatty liver without modulating the lipid profile, as examined via decreased fat deposition, MCP-1 expression, and macrophage accumulation.

Dll4-Mediated Notch Signaling Regulates MCP-1 Expression
Blockade of Dll4 reduced MCP-1 expression in important cardiometabolic tissues/organ, such as atherosclerotic lesions, adipose tissue, and the liver, resulting in reduced macrophage infiltration. Several in vitro experiments confirmed these in vivo results. Loss-of-function experiments using siRNA against Dll4 reduced MCP-1 expression in the murine macrophage cell line RAW264.7 and differentiated 3T3-L1 adipocytes. On the other hand, gain-of-function experiments using overexpression
Dll4 plasmid and immobilized rDll4 promoted MCP-1 expression in these cell types. These results clearly demonstrate that Dll4-mediated Notch signaling regulates MCP-1 expression in macrophages and adipocytes. Furthermore, Dll4-mediated Notch signaling in these cell types seems to be linked with the NF-κB pathway, an important regulator of MCP-1 expression. Several previous studies have suggested a close link between Notch signaling and the NF-κB pathway, but the precise mechanisms are still obscure. Although further investigations are needed to reveal these mechanisms, the Dll4-Notch-MCP-1 axis may be a new target for effective therapies for inflammation in both the cardiovascular system and metabolic organs.

**Dll4-Mediated Notch Signaling Shifts Macrophage Polarization to M1 Polarity**

Evidence suggests the heterogeneity of macrophages, and has identified at least 2 subpopulations: pro-inflammatory M1 macrophages, and anti-inflammatory/non-inflammatory M2 macrophages. Multiple studies have associated M1 macrophages with atherogenesis and plaque instability through collagen loss and calcification in plaques and the development of adipose inflammation and insulin resistance. The concept of M1/M2 macrophage balance was developed in vitro, as gauged by the expression of inflammatory mediators. Recent evidence suggests a wide range of monocyte/macrophage heterogeneity in response to either innate or adaptive immune signals. Despite accumulating in vitro evidence and its large clinical impact, in vivo mechanisms for macrophage activation remain incompletely understood. To explore the role of Dll4-mediated Notch signaling in macrophage polarization, we investigated whether Dll4 antibody treatment affects monocyte/macrophage polarization using a SVF obtained from epididymal fat. Flow cytometry analyses demonstrated that Dll4 blockade tended to decrease the Ly6C-high population, which is generally considered to be pro-inflammatory. F4/80-positive macrophages collected from the SVF of antibody-treated animals tended to express lower levels of pro-inflammatory mediators, including the typical M1 marker iNOS, and slightly higher levels of anti-inflammatory M2 mediators, such as IL-10. Furthermore, peritoneal macrophages obtained from Dll4-antibody-treated animals took up fewer lipids and expressed lower levels of scavenger receptor-A (SR-A) RNA. Accumulation of lipids and SR-A expression are important features of plaque macrophages. Silencing with Dll4 siRNA decreased the expression of typical pro-inflammatory M1 mediators (eg, iNOS and TNF-α) and increased the expression of the M2 marker mannose receptor 1 in RAW264.7 cells. In contrast, enforced Dll4 expression increased iNOS expression and suppressed IL-10 in this cell type. Furthermore, stimulation with immobilized rDll4 increased pro-inflammatory IL-1β and iNOS and decreased IL-10. Collectively, these in vivo and in vitro results suggest that Dll4-mediated Notch signaling skews macrophage polarization toward a pro-inflammatory phenotype.

Assuming that macrophages have plasticity, local microenvironmental cues may tip the M1/M2 balance. Alternatively, distinct subsets of circulating monocytes may be committed to particular M1/M2 fates. Although Notch signaling is required for the appearance of hematopoietic stem cells during early development, canonical Notch signaling is not required for the generation of myeloid cells from hematopoietic stem cells. Similarly, in that study, Dll4 blockade did not alter circulating monocyte numbers and/or the Ly6C-high monocyte subpopulation in the blood and bone marrow. Thus, Dll4 may trigger the pro-inflammatory activation of macrophages in lesions.

**Dll4-Mediated Notch Signaling as a Therapeutic Option**

Dissecting the multiple, intertwined mechanisms of cardiovas-
cular and metabolic disorders, including atherosclerotic vascular diseases, insulin resistance, and fatty liver, should offer insight into potential new therapeutic options. Regulation of the circulatory, metabolic, and immune systems is highly integrated. Exploring the shared and unique mechanisms for inflammation in this disease complex will provide important insight into the development of new therapeutic strategies. We have identified Dll4-Notch signaling as a key mediator for inflammation in the cardiovascular system and metabolic organs. Dll4 may control central elements of the inflammatory and metabolic responses in arteries, fat, and liver, and thus constitutes a unique therapeutic target in cardiovascular and metabolic disorders (Figure 2).

**Acknowledgments**

The studies described in this article were supported by grants from the National Institutes of Health (R01HL107550, to M.A.) and from the American Heart Association (Grant-In-Aid, 0655878T, to M.A.), by a Postdoctoral Fellowship Award for Research Abroad from the Japanese Heart Foundation (to D.F.), by the Japan Society for the Promotion of Science (to D.F.), and by the Uehara Memorial Foundation (to D.F.). We thank Sara Karwacki for her editorial assistance.

**References**

40. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial


